
Oncotarget
Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.
Oncotarget is now indexed by MEDLINE, PubMed and PMC/PubMed.
Read about the Oncotarget Scientific Integrity Process: https://www.oncotarget.com/scientific_integrity/
Latest episodes

Oct 18, 2023 • 4min
The Nuclear Envelope and Breast Cancer Metastasis
Researchers discuss the role of nuclear morphology in breast cancer metastasis and the importance of immunofluorescence staining. They explore the physical barriers faced by cancer cells during metastasis and highlight the correlation between aemarin expression and survival time in breast cancer patients.

Oct 17, 2023 • 4min
GBP3-STING Interaction in Glioblastoma Coordinates Poor Response to Temozolomide
This podcast discusses the challenges of temozolomide treatment for glioblastoma and the role of the GBP3-STING interaction in the development and recurrence of this tumor. It explores the impact of GBP3 upregulation on temozolomide response, which is associated with worse survival outcomes.

Oct 12, 2023 • 9min
HER3: A Vital Target in Cancer Treatment
Dr. Omkar Desai discusses the significance of HER3 in promoting cancer cell growth and chemo resistance. Challenges in translating preclinical studies on HER3 targeted therapies to clinical trials and HER3 overactivation as a resistance mechanism in cancer cells are explored. Emphasizing the importance of identifying HER3 expression and gene fusions as predictive biomarkers and developing combination therapies to combat resistance.

Oct 11, 2023 • 3min
Suppression of Cancer Stemness & Drug Resistance via BRAF/EGFR/MEK Inhibition in Colorectal Cancer
Researchers explore the role of cancer stemness in drug resistance of colorectal cancer cells. They found that a triple combination treatment against BRAF, EGFR, and MEK significantly reduced stemness and oncogenic signaling pathways in these cells.

Oct 9, 2023 • 3min
STAT3 as a Target in H3K27M-mutant DMGs
Researchers discuss the potential of targeting STAT3 as a therapeutic approach for pediatric H3K27M-mutant DMGs, a challenging type of brain tumor with limited treatment options.

Oct 5, 2023 • 6min
Blog: Genetic Insights into Early Breast Cancer in Kazakhstan
This podcast explores the genetic factors that contribute to early breast cancer in the Kazakh population, highlighting the importance of personalized risk assessment. The study identifies specific variants in cancer predisposing genes, providing valuable insights for genetic testing.

Oct 4, 2023 • 2min
UGDH in Clinical Oncology and Cancer Biology
In this podcast, researcher Meghan J. Price discusses UDP-glucose dehydrogenase (UGDH) and its role in tumor progression. The review paper explores UGDH as a molecular indicator of tumor progression, its involvement in cancer signaling pathways, and potential therapeutic targets and prognostication markers.

Oct 3, 2023 • 3min
An Ancient Anti-cancer Mechanism: DISE
Researchers Monal Patel and Marcus E. Peter from Northwestern University discuss an ancient anti-cancer mechanism called DISE that senses mutational load in cancerous cells. They explore its potential in cancer treatment by targeting essential survival genes.

Sep 27, 2023 • 3min
Reassessing COVID-19 Precautions in 2023
The podcast discusses the risks faced by patients with hematologic malignancies in relation to COVID-19, including poor response to vaccination. It addresses concerns about outdoor activities and large gatherings, emphasizing the importance of balancing infection risk with social isolation challenges.

Sep 25, 2023 • 3min
Four Novel Receptors May Link Endometrial Cancer to PCOS
Researchers investigate links between endometrial cancer and polycystic ovary syndrome through transcriptomic analysis, exploring upregulation of the IGF-1 gene in PCOS endometrium and proposing a transcriptomic atlas for uncovering molecular mechanisms.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.